Exact Sciences Corporation maintained revenue guidance for the full year of 2024. For the period, the company has maintained its revenue guidance of $2.810 billion to $2.850 billion, assuming: screening revenue of $2.155 billion to $2.175 billion, and precision oncology revenue of $655 billion to $675 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
44.42 USD | -2.26% | -5.19% | -39.74% |
May. 24 | Sector Update: Health Care Stocks Advance Pre-Bell Friday | MT |
May. 24 | Exact Sciences to Present New Data at Oncology Annual Meeting Confirming Prognostic Value of Breast Cancer Test | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-39.74% | 8.39B | |
+0.61% | 3.32B | |
+3.94% | 2.48B | |
-19.81% | 2.06B | |
-24.03% | 1.59B | |
+32.98% | 1.15B | |
-7.21% | 704M | |
+10.17% | 678M | |
-30.92% | 508M | |
-6.86% | 273M |
- Stock Market
- Equities
- EXAS Stock
- News Exact Sciences Corporation
- Exact Sciences Corporation Maintains Revenue Guidance for the Full Year of 2024